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Aquation free energy profiles of neutral cisplatin and cationic mono-
functional derivatives, including triaminochloroplatinum(II) and cis-
diammine(pyridine)chloroplatinum(II), were computed using state of the art
thermodynamic integration, for which temperature and solvent were accounted
for explicitly using density functional theory based canonical molecular dynamics
(DFT-MD). For all the systems the ”inverse-hydration” where the metal center
acts as an acceptor of hydrogen bond has been observed. This has motivated to
consider the inversely bonded solvent molecule in the definition of the reaction
coordinate required to initiate the constrained DFT-MD trajectories. We found
that there exists little difference in free enthalpies of activations, such that these
platinum-based anticancer drugs are likely to behave the same way in aqueous
media. Detailed analysis of the microsolvation structure of the square-planar
complexes, along with the key steps of the aquation mechanism are discussed.
I. INTRODUCTION
The discovery of the anticancer activity of cisplatin (Scheme 1) during the 60’s has
promoted fast development of platinum(II)-based drugs which are currently found in
chemotherapy regimens (see Refs. 1–4 for reviews). Despite few successes for some of
them in curing specific cancers, eg. the treatment of testicular cancer with cisplatin, their
efficiency against the broad spectrum of carcinoma remains limited. The main challenges to
overcome are: (1) the elimination of the severe side effects related to their poor selectivity
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ar
X
iv
:2
00
3.
01
41
8v
1 
 [p
hy
sic
s.c
he
m-
ph
]  
3 M
ar 
20
20
2with respect to the tumor cells, and (2) the resistance —either intrinsic (static) or evolution-
ary (dynamic)—, observed for some types of cancer.5–7 Solving the first problem requires the
design of new drug delivery strategies,3,4 which ideally prevents the degradation of platinum
complex in the blood stream and allows for a precise targeting of the tumor tissue. Solution
to the second problem implies heuristic methods, such as the structure-activity relationship
(SAR),2,8 from which a huge number8 of platinum(II)-based drugs and platinum(IV)-based
prodrugs were synthesized and tested as many attempts to mimic the cisplatin’s mechanism
of action while trying to improve the cytotoxic properties. As a result of 30 years of trial
and error less than 30 platinum drugs have been considered for clinical trials, with only 2 of
them (carboplatin and oxaliplatin) approved wordwilde for clinical used.1,4 Whereas high-
throughput synthesis and screening9 of drug candidates may provide rapid —but partial—
solutions to an urgent problem, understanding and controlling every details of cisplatin’s
mechanism constitutes a safer —but far more longer— route towards a rational design of a
universal platinum-based anticancer molecule. The process by which cisplatin (and bifunc-
tional derivatives) leads to cell death is now rather well understood.10,11 It is divided into
4 main steps: (i) the cellular uptake, (ii) the aquation/activation (Scheme 1) in the cellular
media, (iii) the DNA platination, that is, bifunctional intra- and interstrand crossed-links
via the fomation of 2 covalent bonds between the metal center and the purine bases, and (iv)
the DNA-damage recognition initiating apoptosis, or cell-cycle arrest eventually followed
by an attempt to repair the lesion. In elucidating each step of the mechanism, atomistic
computations and simulations based on either (classical) molecular, quantum, or mixed
molecular/quantum mechanics can provide important insights.
FIG. 1. Aquation reaction of cisplatin (1) and monofunctional derivatives (2).
At the pure quantum mechanics level of theory, some of the efforts were devoted to
investigate the hydration structure of the square-planar Pt-complexes12–14 in response
to some experimental evidence15,16 showing unusual bonding situation —referred as to
inverse-hydration— where the Pt atom acts as a hydrogen-bond acceptor. Energetic
contributions17–19 and topological analysis,20 along with minute details on the influence
of the bulk solvation effects have been extensively discussed in literature.19,21,22 Another
interest which is also closely related to our concern is the activation of cisplatin after the
cellular uptake of the platinum drug. The aquation reaction (also loosely called hydrolysis)
represented on Scheme 1 through the substitution of one or both chloride ligands of cisplatin
by water molecules was recognized as a crucial step to initiate DNA platination.23 The proof
of concept is carboplatin24–26 featuring the cyclobutanedicarboxylate in replacement of the
chloride leaving ligands of cisplatin. It demonstrates much more slower aquation and DNA
platination rates but displayed similar crossed-link sites.27
To access more details on the aquation of cisplatin and derivatives, many theoretical
works have focused on computing activation barriers using static molecular clusters and
implicit solvation models.28 When applied for modelling aqueous reactions, insights arising
from this type of computations remain limited since they do not account properly for the
3FIG. 2. Structures cationic monofunctional platinum complexes. Note that phenantriplatin has
not been investigated in this work.
dynamic reorganisation of solvation shell surrounding the molecule, especially when the
solvent is one of the reactant. More advanced but computationally demanding methods can
be envisaged where bulk and microsolvation effect are treated on equal footing using density
functional theory molecular dynamics (DFT-MD) along with free energy path evaluation
based on metadynamics further refined by umbrella sampling.29,30 Alternatives to DFT-
MD, such as the reference interaction site model self-consistent field31,32 (RISM-SCF) can
also be employed.33
From the last ten-years research focussing on reducing the tumor-cell resistance to bi-
functional cisplatin and derivatives, it has been shown that monofunctional analogues34–36
can be considered as potent candidates.37–39 Monofunctional platinum(II)-based drugs are
cationic square-planar complexes (Scheme. 2) of formula [Pt(NH3)2(N-heterocycle)Cl]
+, de-
riving from the triammine-chloro precursor [Pt(NH3)3Cl]
+, later referred as to aminoplatin.
In a systematic investigation of the cancer-cell responses with respect to the heterocyclic
N-donor ligand bound to the metal, it has been demonstrated40 that the size and the ar-
rangement of the aromatic rings affects drastically the cytotoxic and selectivity properties
of the monofunctional platinum(II) drugs. As a matter of fact, whereas aminoplatin was
found to be biologically inactive, phenanthriplatin, and to a lesser extent pyriplatin, presents
a remarkable potency,41 exceeding in the majority of the cases the anticancer activity of
cisplatin.40,41
This work aims to investigate the aquation reaction of Pt(II) complexes using state of the
art thermodynamic integration coupled to DFT-MD simulations to determine if cationic
monofunctional derivatives present differences in the free energy profiles and mechanism
of reaction. The paper is organized as following: Section 2 provides methodological and
computational aspects related to the DFT-BOMD simulation and blue moon ensemble
(BME) integration. Results and discussion are presented in Section 3. The paper concludes
with a brief summary of the key findings and an outlook.
II. COMPUTATIONAL DETAILS
A. DFT-BOMD simulations
All the DFT-MD simulations reported in this article were performed on the Born-
Oppenheimer (BO) surface, where the Kohn-Sham (KS) self-consistent-field (SCF) equa-
tions are solved at each step of the dynamics using the Conquest code.42–44 A strictly
localized (atomic-like and finite range) numerical double-ζ basis set45–47 including polarisa-
tion functions (DZP) for expanding the valence wavefunctions along with norm-conserving
pseudopotentials48 (NCPP) were especially designed for this work. Thereafter, this basis
set will be referred as pseudo-atomic orbitals (PAO). Using a benchmark of isolated Pt
complexes, reliability of the PAOs were checked against molecular calculations based on
gaussian-type orbitals (GTO). Additional computational parameters related to the PAOs
and NCPPs generation along with their assessments can be found in the Sec. S1 of the
Supporting Information (SI). The KS-SCF equations were solved within the framework
4of the generalized gradient approximation (GGA) of the exchange-correlation functional
proposed by Perdew, Burke, and Ernzerhof (PBE).49 This choice of GGA functional was
more pragmatic than idealistic. It is well established (see Refs. 50,51 for recent studies)
that the PBE functional yields to a ”glassy” state of liquid water at ambient temperature
preventing a fully quantitative agreement with experiments. Nevertheless, also important
for this work, it has been demonstrated that the same functional is able to reproduce the
inverse-hydration feature.52
Solvation of the platinum complexes has been modeled using cubic simulation boxes with
63 water molecules adapted in size to reach an average density of 1.0 g·cm−3. For cationic
complexes, the excess of positive charge was balanced by substituting water molecule with
hydroxide anion keeping the overall charge of the supercell neutral. For the DFT-BOMD
simulations, ionic cores were propagated using the velocity Verlet algorithm53 with a time
step of 0.5 fs, for which a SCF convergence criteria of 10−7 on the residual of the electronic
density, and a grid spacing of about 0.20 au were found sufficient to prevent any energy
drift during microcanonical simulations. The same set of convergence parameters were
used for NVT -ensemble simulations using a Nose´–Hoover chain54,55 of 5 thermostats with
a frequency of 500 cm−1.
B. Blue moon ensemble integration
The hydrolysis free energy profiles of cisplatin and its derivatives were calculated using
thermodynamic integration via the blue moon ensemble (BME) technique.56 Given a reac-
tion coordinate, ξ ≡ ξ({ri}), which in general depends on a subset of the N atomic positions
{ri}, the variation of free energy between some initial state, ξ0, up to the current value of
ξ can be expressed as:
∆F (ξ, T ) =
∫ ξ
ξ0
(
∂F (ξ;T )
∂ξ
)
ξ′
dξ′, (1)
Integration is performed numerically through the sampling of the reaction coordinate using
a discret set of nξ′ target values {ξ′}. The free energy gradient —also referred to as (minus)
the mean force— in Eq. (1) is evaluated for each ξ′ from a constrained MD trajectory where
ξ − ξ′ = 0 is enforced. Following BME Lagrangian formulation of Sprik and Ciccotti,57 the
mean force writes (
∂F (ξ;T )
∂ξ
)
ξ′
=
〈Z−1/2(− λξ + kBTG)〉ξ′
〈Z−1/2〉ξ′
, (2)
for which kB and T are the Boltzmann constant and temperature, respectively. The La-
grange multiplier, λξ, associated with constrained coordinate ξ, defines the strength the
constraint force updated at each MD step.58–60 The remaining terms are given by,
Z =
N∑
i=1
1
mi
(
∂ξ
∂ri
)2
, (3)
G =
1
Z2
N∑
i=1
N∑
j=1
1
mimj
∂ξ
∂ri
· ∂
2ξ
∂rirj
· ∂ξ
∂rj
. (4)
where mi designates the mass of the ith nucleus. In Eq. (1), the notation 〈·〉ξ′ stands for
the canonical ensemble average performed for each target value ξ′. Around 20 values were
used for the reaction path discretization. Ensemble averages performed at T = 310 K were
obtained from production runs of 2.5 ps subsequent to 1.0 ps of equilibration. Free energy
errors were estimated by the method of Jacucci and Rahman.61
5III. RESULTS AND DISCUSSION
A. MD analysis and reliability
TABLE I. Comparison of selected structural parameters of the solvated bi and monofunctional
cisplatin derivatives obtained with the PBE functional using various methods. For BOMD simu-
lations, mean distance and angle values are given along with their respective standard deviations.
Inequivalent nitrogen atoms are numbered according to Schemes 1 and 2.
Complex Method Basis Distance (A˚) Angle (deg)
cisplatin Pt–N Pt–Cl N–Pt–N Cl–Pt–Cl
BOMD-NVE PAO-DZP 2.08± 0.04 2.37± 0.03 91.0± 4.0 92.5± 3.4
CPMD-NVEa PW 2.09± 0.04 2.35± 0.03 90.4± 4.1 92.3± 4.3
Static-PCMb GTO-DZP 2.07 2.34 92.7 94.7
Static GTO-DZP 2.09 2.30 99.1 95.7
Static PAO-DZP 2.10 2.34 98.5 96.0
mono-aqua cisplatin Pt–N(1)[Pt–N(2)] Pt–Cl Pt–O N–Pt–N
BOMD-NVE PAO-DZP 2.05[2.08]± 0.03[0.05] 2.36± 0.03 2.10± 0.07 91.4± 4.5
Static-PCM GTO-DZP 2.02[2.07] 2.32 2.10 93.5
Static GTO-DZP 2.03[2.11] 2.28 2.10 97.2
Static PAO-DZP 2.04[2.12] 2.32 2.11 96.6
aminoplatin Pt–N(1)[Pt–N(2)] Pt–Cl N(1)–Pt–N(2) N(1)–Pt–Cl
BOMD-NVE PAO-DZP 2.06[2.08]± 0.04[0.04] 2.40± 0.03 90.5± 4.2 89.5± 4.2
Static-PCM GTO-DZP 2.06[2.08] 2.33 91.2 88.8
Static GTO-DZP 2.07[2.12] 2.28 93.6 86.4
Static PAO-DZP 2.08[2.13] 2.32 93.4 86.3
pyriplatin Pt–N(1)[Pt–N(2)] Pt–Cl Pt–N(3) N(1)–Pt–N(2)
BOMD-NVE PAO-DZP 2.04[2.07]± 0.03[0.04] 2.37± 0.03 2.07± 0.03 90.3± 4.1
Static-PCM GTO-DZP 2.07[2.08] 2.33 2.02 91.3
Static GTO-DZP 2.08[2.10] 2.28 2.02 95.0
Static PAO-DZP 2.09[2.13] 2.32 2.02 95.0
aResults obtained in Ref. 13 using the Car-Parrinello (CP) approach as implemented in Quantum ESPRESSO62.
The implementation is based on planewave (PW) basis set and pseudopotentials. The same model has been used
for the BOMD and CPMD simulations, eg. box size and number of atoms. b’Static’ refers to gas-phase optimized
structures including (or not) an implicit water-solvent treatment based on the Polarizable Continuum Model
(PCM) as implemented in GAUSSIAN0963.
To assess the quality of our DFT-BOMD simulations, the liquid structure of the solvated
Pt-complexes were analysed via the radial distribution function (RDF) —leading to the
pair correlation function g(r)— and the power spectral density (PSD) of the velocity au-
tocorrelation function (VACF) —leading to the vibrational density of states (VDOS). The
methodology used for the calculations of these properties can be found in the SI of Ref. 52.
For each system, RDFs (VDOS) were computed from a NVT (NVE ) production run of 10
ps performed after a NVT equilibration step of 15 ps. The PSD was refined using the Welch
window function with 8 non-overlapping segments of 512 data points.64 Analysis and a brief
discussion of the solvent RDFs and VDOS in light of previous studies are given in Sec. S2
of the SI. Below we shall concentrate on the solute structural and vibrational signatures.
Selected mean bond distances and angles obtained from the microcanonical BOMD sim-
ulations are collected in Table I for all the Pt-based reactants investigated in this work.
For cisplatin, when compared to previous DFT-MD simulations using the same XC func-
tional but a different implementation,13 a nice agreement is observed. By comparing across
the set of platinum complexes the deviations of the Pt-ligand mean bond distances and
angles with respect to gas phase optimized strutures, we can isolate two systematic effects
of aqueous solvent: (i) an increase of the Pt−Cl bond length, (ii) a net decrease of the
N−Pt−N angles. Analyses of the g(r) associated to the solvent-solute interactions given in
Figure 3 allows for interpreting the systematic effects in terms of ligand hydration shells.
6As already discussed in Ref. 52 for cisplatin, the NH· · ·Ow g(r) shows that the first and
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FIG. 3. Selected g(r) describing the solute-solvent dynamical structures for the solvated bi and
monofunctional cisplatin derivatives complexes studied in this work.
TABLE II. Analysis of the ligand–water g(r) calculated for solvated cisplatin and derivatives. The
maxima (rmax) and the integration radii (rint) are given in A˚. The coordination number (n) were
evaluated by integrating the corresponding g(r) up to rint. The atoms labeled Ow and Hw refer
to water molecules. The Cl· · ·Hw and NH· · ·Ow RDFs are represented on Figures 3(a) and (b),
respectively.
Complex Pt(NH3)2Cl2 [Pt(NH3)2(OH2)Cl]
+ [Pt(NH3)3Cl]
+ cis-[Pt(NH3)2(pyridine)Cl]
+
Peaka first second first second first second first second
Cl· · ·Hw
rmax 2.3 (3.9/4.4)* 2.3/2.7s (4.3/4.9)* 2.4/2.9s (5.1)* 2.4 (4.5/5.1)*
rbint 2.8 5.0 3.0 5.0 3.1 5.0 2.9 5.0
n 1.8 22.7 2.2 22.6 2.1 19.0 1.9 19.6
NH· · ·Ow
rmax 1.9 3.4 1.9/2.4s 3.5 1.9 3.5/3.9s 1.9 3.4/4.3s
rint 2.6 4.5 2.6 4.5 2.5 4.5 2.6 4.5
n 0.7 7.7 0.8 7.6 0.6 7.6 0.6 6.7
aAsterisks indicate that the peak(s) is(are) not well resolved. Peak shoulder is indicated by s. bFor the first
integration, rint was fixed to the closest minimum following the first maximum. Beyond these radii fixed values
of rint = 5.0 and 4.5 A˚ for the Cl and NH coordination numbers respectively, were considered.
second hydration shells of each NH3 group integrates around 1 and 8 water molecules, re-
spectively. This also applies to the other platinum complexes (cf. Table II). The fact that
the ligand solvation shell is only weakly affected by the variety of ligands bonded to the
Pt atom and the charge state of the solute is confirmed by the Cl· · ·Hw g(r) plotted on
Figure 3, where each Cl atom integrates in the first neighbor region 2 waters molecules,
independently of the system. The second shell is more difficult to discussed due to the
7limited resolution of the peaks. Nevertheless, in light of this results, (i) can be directly
attributed to the Cl· · ·Hw hydrogen bonds perturbing the Pt−Cl bond strength, whereas
(ii) is an indirect consequence of the ammonia group hydration where the preferential ar-
rangement of NH3 from a static gas-phase optimisation —with one of the hydrogen atom
pointing towards the closest Cl lone pair— is lost, relaxing the constraint on the Cl−Pt−N
angles of the square planar complexes. Note that, as shown in Table I, a polarizable contin-
uum model (PCM) applied to static isolated solute is able to simulate these two features,
demonstrating the concomitant contributions of specific and non-specific solvent effect. In
Table III is compared selected structural parameters extracted from the RDFs for cisplatin
and the mono-aqua derivative in regard to the previous studies based on DFT-MD.13,22,30
Even if the results were obtained from different implementations and exchange-correlation
functionals —preventing an unbiased comparison— we observe an overall agreement which,
besides validating the reliability of our implementation, suggests minor impact of (i) the
GGA functional (cf. Ref.30 DFT-MD simulations performed with BLYP) and (ii) inclusion
of the empirical dispersion correction (cf. Ref. 22 ; DFT-MD simulations performed with
PBE-D3) on the qualitative description of the ligand first hydration shells.
TABLE III. Comparison of selected structural parameters (in A˚) calculated from the ligand–water
RDFs of solvated cisplatin obtained from various DFT-MD simulations. See caption and footnotes
of Table II for more details.
Pt(NH3)2Cl2 [Pt(NH3)2(OH2)Cl]
+
Method PBE/BOMD PBE/CPMD BLYP/CPMD PBE+D3/BOMD PBE/BOMD BLYP/CPMD PBE+D3/BOMD
Basis PAO/NCPP PW/USPP PW/NCPP mixed GTO-PW/NCPP PAO/NCPP PW/NCPP mixed GTO-PW/NCPP
Reference this work [13] [65] [22] this work [65] [22]
N· · ·Ow
rmax 3.0 3.2* 2.9 3.0 2.9 2.9 3.0
rint 3.3 3.4* – 3.6 3.7 – 3.5
n 2.4 2.5* 2.9 3.6 3.2 3.5 3.5
NH· · ·Ow
rmax 1.9 1.9 – – 1.9/2.4s – –
rint 2.6 2.5 – – 2.6 – –
n 0.7 0.7 – – 0.8 – –
Cl· · ·Ow
rmax 3.4* 3.3 3.2* – 3.5 3.1 –
rint 3.7* 3.7 – – 3.9 – –
n 2.8* 2.6 2.9* – 3.8 3.4 –
Cl· · ·Hw
rmax 2.3 2.3 2.3 2.3 2.3/2.7s 2.3 2.3
rint 2.8 2.9 – 2.8 3.0 – 2.9
n 1.8 2.2 1.7 2.2 2.2 2.4 2.2
Another important step in the assessment process of our DFT-MD simulations is to ensure
that the characterisitic vibrational modes of the solute and solvent were properly activated.
Partial VDOS obtained for cisplatin, aminoplatin and pyriplatin are plotted on Figure 4.
As external references, Raman and infra-red theoretical spectra of the isolated molecules
are also reported. They were calculated on top of the stationary points obtained at the
PBE-GTO-DZP level of theory including a PCM.63 Here, it is worth to recall that VDOS
heights computed from the Fourier transform of the VACFs are not to be compared with
spectroscopic intensities, and to emphasize that even if the underlying semiclassical theory
involved in evaluating the VDOS —based on the classical propagation of the nuclei on
the BO potential energy surface— is quite different from the response function computed
from analytic (or numerical) derivatives —based on the harmonic approximation— their
comparisons remain valuable for routine checks. As expected, cisplatin and aminoplatin
vibrational spectrum are similar in many respects since the Pt center is surrounded by the
same type of ligands. In both cases the bond-stretching modes: N−H (> 3200 cm−1),
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FIG. 4. Comparison between Raman and infra-red theoretical spectra obtained from a molecular
approach along with an implicit sovent model and the partial vibrational density of states (VDOS)
extracted from the BOMD simulations.
Pt−N (∼ 500 cm−1) and Pt−Cl (∼ 300 cm−1) are observed as well as the NH3 rocking
and symmetric/asymetric deformation signatures, found around 800 and 1300/1300 cm−1,
respectively.13,66,67 For pyriplatin, the complexity of the vibrational spectra is increased
by the contributions of the pyridine ligand, with the stretching modes: C−H (∼ 3250
cm−1), C−C/C−N (in the range 1100 to 1500 cm−1), the skeletal bending modes along
with the out-of-plane C−H wagging (∼ 1000 cm−1 and 700 cm−1). As shown on Figure 4,
VDOSs extracted for the DFT-BOMD is in fair accordance with the theoretical spectra,
such that, given the level of theory PAO-DZP-PBE, we can be confident in the reliability
of our simulations when applied to free energy profiles calculation.
B. Inverse hydration
We shall now focussed on the inverse-hydration taking place in the axial region of the
square-planar Pt(II) complexes (Scheme 5). It can be observed at the beginning of each
MD movies provided in the SI. The hydrogen-like bonding between a water molecule and
the metal center following a H-ahead orientation is easily revealed by analysing the gPtO(r)
and gPtH(r) available on Figure 3. First we note that for all the systems investigated
in this work a non-negligible probability of having a Pt· · · (H2O)w contact is observed at
an intermolecular distance of around 2.4 A˚. The poorly-resolved peaks obtained for the
Pt· · ·Hw (Pt· · ·Ow) g(r) in the range 2 to 3 (3 to 4) A˚ illustrate the motion or/and the
exchange of H2O with other solvent molecules in close proximity, eg. those available from
the Cl hydration shell(s). Another important insight is brought by the height of the peaks,
cf. the Pt· · ·Hw (Pt· · ·Ow) g(r) around 2.4 (3.4) A˚, indicating a net decrease of the contact
occurrence when going from neutral to positively charged complexes. Quantification of
the Pt· · ·H2O contact is provided in Table IV for the bi- and monofunctional platinum
9TABLE IV. Analysis of the Pt–O and Pt–H RDFs calculated for cisplatin and derivatives along
with the coordination numbers n ; cf. caption of Table II and Figures 3(c) and (d) for the plots.
Complex Pt(NH3)2Cl2 [Pt(NH3)2(OH2)Cl]
+ [Pt(NH3)3Cl]
+ cis-[Pt(NH3)2(pyridine)Cl]
+
Peak first second first second first second first second
Pt· · ·Hw
rmax 2.5 3.0 2.4 (2.8/3.2) 2.4 na 2.3 (3.0/4.0)
rint 2.6 3.3 2.6 3.3 2.6 3.3 2.6 3.3
na 0.5 1.4 0.2 0.9 0.2 0.7 0.1 0.7
Pt· · ·Ow
rmax 3.5 4.3 na 4.2 3.4 (4.2/4.5) 3.3 (3.9/4.6)
rint 3.6 4.6 3.6 4.6 3.6 4.6 3.6 4.6
na 0.7 6.4 0.7 7.0 0.5 6.7 0.4 5.3
aSince RDFs are poorly-resolved, fixed rint values were considered for the first and second integration.
anticancer drugs, through the evaluation of the Pt(H) and Pt(O) coordination numbers,
noted nPtH and nPtO, respectively. Due to the broad shape of the peaks, a set of two
integration radius (rint in Table III) were used independently of the complex. For neutral
cisplatin, nPtH is evaluated to be within the interval [0.5, 1.4], along with [0.7, 6.4] for
nPtO. Note that for larger rint, it is likely that the value of the coordination numbers
also incorporate H2O molecules from the NH3 and Cl ligand solvent shells. For the set
of positively charged complexes, the probability of Pt· · · (H2O)w contact is significantly
reduced from nPtH = [0.2, 0.9] for mono-aqua cisplatin to nPtH = [0.1, 0.7] for pyriplatin. For
this set, variations of nPtO seems to be more affected by the type of ligand, for which, mono-
aqua cisplatin nPtO presents values similar to its neutral parent, whereas for aminoplatin
and pyriplatin the coordination number is lowered to [0.5, 6.7] and [0.4, 5.3], respectively.
These results corroborate the work of Kroutil et al.22 which showed, among other findings,
that: (i) Hw coordination number decreases with increasing positive charge of the complex,
(ii) given a state charge (+1 in our case) the H-ahead orientation toward the Pt atom
is strongly dependent on the hydrogen bond network formed by the nearby ligands. We
refer the reader to this reference for extended discussion on this topic which also includes
energetics consideration.
FIG. 5. Structural arrangements of the incoming water molecule at the early stages of the aquation
reaction.
Concerning now the second part of this work dealing with evaluation of the hydrolysis
free energy profiles of reaction (1) and (2), among all the water molecules accessible within
the solute first solvation shell, it seems quite reasonable to consider the inversely bounded
water molecule as the reactant.
C. Hydrolysis free energy profiles
The choice of the reaction coordinate ξ is an important point in BME integration which
can be a delicate issue when little is known about the chemical reaction. In this work, we
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have relied on the broad (experimental and theoretical) litterature agreeing that cisplatin
aquation(s) is a one step process, eg. the SN2-like mechanism, for which the reactants (R)
and products (P) are connected by a single transition state (TS). From this assumption,
a rapid analysis of the corresponding saddle point (optimized with a quantum chemistry
code) shows that the characteristic imaginary frequency is related to the Cl−Pt−O anti-
symmetric stretching mode together with the in-plane rotation of the NH3 group in trans
position (Scheme 5). This led us to consider the difference of distance68–71 for the reaction
coordinate:
ξ = ||rPt − rO|| − ||rPt − rCl||, (5)
where O is the oxygen atom of the H· · ·Pt bonded water molecule. Configurations used
to initiate the constrained DFT-BOMD trajectories were extracted from the canonical en-
semble simulations discussed in Sec. III B. Note that variations of (Helmholtz) free energies
as computed from Eq. (1) were directly converted to (Gibbs) free enthalpies since we did
not observe any strong variation of pressure during the thermodynamic integration which
would have significantly modified the final enthalpy values.
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FIG. 6. Free energy path for hydrolysis of cisplatin and derivatives in water at T = 310 K using
the blue-moon ensemble approach. Curves were interpolated with cubic splines.
Free energy reaction paths are displayed in Figure 6 along with the free enthalpies of ac-
tivation (∆‡G) and reaction (∆rG) collected in Table V. Concerning the second hydrolysis
of cisplatin performed via the monoaqua complex, two set of BME calculation were pro-
duced: the first with Cl− as counterion following the first hydrolysis (later abbreviated by
monoaqua[Cl]), the second from afresh NVT equilibration in which Cl− has been replaced
by OH− (abbreviated by monoaqua[OH]). From Figure 6 we observe very similar energy
profiles from the attack of the water molecule up to the transitions states. Evaluated ∆‡G
for cationic monofuntional species are found to be lower of about 1 kcal · mol−1 than the
reference value of 25 kcal ·mol−1 obtained for the neutral parent. The presence of the Cl−
counterion during the second hydrolysis of cisplatin tends to slightly decrease the barrier,
but without dramatic effect. Indeed, major deviations between aquation profiles are found
after the TS. This lead to noticeable differences in the values of ∆rG, for which we found
that the aminoplatin aquation is endothermic by 3 kcal ·mol−1 compared to 8 for cisplatin,
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pyriplatin and moaqua[Cl], whereas for moaqua[OH] the free enthalpy of reaction reach the
value of 10 kcal ·mol−1. It is tempting to compare these values to available experimental
data. This should be done with lots of care owing to: (i) the large amount of papers dealing
with this subject, which comes generally with the same amount of differences in experimen-
tal condition, (ii) the limitations of our model in reproducing these conditions. As a result,
Reactant Counterion ∆‡G (kcal · mol−1) ∆rG (kcal · mol−1)
cisplatin none 25.3 ± 0.4 7.9 ± 0.7
mono-aqua cisplatin OH− 25.4 ± 0.6 10.2 ± 1.1
Cl− 24.5 ± 0.6 8.0 ± 1.0
aminoplatin OH− 24.5 ± 0.8 2.9 ± 1.3
pyriplatin OH− 24.4 ± 0.5 8.1 ± 0.9
TABLE V. Free enthalpies of activations and reactions for aquation of cisplatin and derivatives in
water at T = 310 K using the blue-moon ensemble approach.
even if the pH of the aqueous media can impact significantly the kinetic of the reactions —as
shown in the comprehensive study of House and coworkers72–74— we must emphasize that
the precision reach by the BME simulations remains far from the chemical accuracy required
to discuss variation in activation energies below 1 kcal ·mol−1.? From Refs. 72,73,75–79 we
can establish a consensus on the experimental free enthalpy (at ambient temperature) for
both, the first and second aquation, to be between 23 and 24 kcal ·mol−1. The experimental
values for the cationic aminoplatin and pyriplatin are expected to be within this range.40 A
consensus on the endothermic property of the aquation reactions can also be drawn, with
∆rG for cisplatin experimentally evaluated to be in the range 3-10 kcal ·mol−1.72,73,78 Our
results which are in line with experimental data should not be overinterpreted. Whereas
we are quite confident in the reliability of the computed BME activation enthalpies, the
thermodynamic quantities must not be considered as definitive. The limited size of cell can
not prevent intramolecular ion pair contact to occur (the outermost Cl· · ·Pt distance being
of 6.5 A˚). For aminoplatin, the larger error bars on the integrated free energy observed at
the late stages of the reaction suggest that the final ∆rG is not fully converged.
In order to gain some insights into the reactants motion and solvent reorganisation along
the reaction path, visual inspection of the constrained MD movies is quite instructive.
Representative examples are provided in the SI for cisplatin and pyriplatin. For all the
complexes investigated similar trends in the evolution of skeletal bond parameters and
solvent shell relative to the reactant constrained dynamics were found. The study cases
of cisplatin and pyriplatin aquations are depicted in Figures 7 and 8, where the variation
of selected structural parameters are plotted as a function of ξ. At the beginning of the
reaction (ξ < 0), the square planar structure with the inverse-hydration is globally conserved
in both cases. In this regime, for cisplatin, the net decrease of the Pt· · ·O bond length
(dPtO = 3.8→ 2.7 A˚) is accompanied by a weaker increase of the Pt· · ·Cl distance (dPtCl =
2.4→ 2.7 A˚) whereas the N−Pt−O (α), O−Pt−Cl (β) and Cl−Pt−N (γ ) angles oscillate
around mean values of 100, 85 and 175◦, respectively. These observations also hold for
pyriplatin with slight differences in values. For cisplatin, magnitude of the variations along
ξ observed for α and β, which are much higher than for γ, indicates that the constrained
water molecule remains free to visit the axial region of the square-planar complex. It seems
to be less pronounced for pyriplatin. The difference in lability of the inversely bonded H2O
between the two complexes is apparent when comparing the standard deviation (std) of
the Pt· · ·H distances plotted on Figure 8. For cisplatin we occasionally observe that these
distances collapse towards a single value, eg. at ξ = (−1.2,−0.5), indicating H-atom swap
through the rotation along the axis perpendicular to the H2O molecular plan. The variations
of the H−O−Pt angles (θ1, θ2) with mean values of about (20, 100)± 20◦ for cisplatin, and
(10, 110) ± 5◦ for pyriplatin confirm the preferential inverse-hydration orientation, and for
the later case, the reduced mobility of the H2O-reactant.
When approaching the transition state located at ξ = 0.36 and 0.43 A˚ for cisplatin and
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FIG. 7. Ensemble average of the skeletal bond angles and distances as a function of the BME
coordinate obtained for cisplatin (left) and pyriplatin (right) aquation. Vertical bars correspond
to the standard deviations. Free energy profile along the reaction path has been included to guide
the eye.
pyriplatin respectively, the inversely bonded H2O is activated via the ion-dipole orientation
depicted in Scheme 5 with dPtO ' 2.5 and dPtH ' 3.0 A˚. For cisplatin, when ξ > 0.1 (ξ > 0.3
for pyriplatin), the rotation of the NH3 group is engaged leading to the TS. Note that, within
the TS region, reported Pt· · ·H distances and angles are weakly affected compared to the
rotation angles (α, γ). By identifying on Figure 7 the skeletal parameters corresponding to
the maximum of free energy, it seems that the cisplatin TS is closer to a square pyramidal
structure than a trigonal bipyramid as observed in gas phase calculations.28 With α '
γ ' 140◦ a trigonal pyramid can be clearly assigned to pyriplatin. For ξ > 0.9, the water
molecule is fully coordinated to the metal center with a typical bond length dPtO ' 2.1
A˚, and the Cl anion is released to bulk water. Inspection of the cisplatin BME integration
movie at ξ = 1.15 reveals that the singularity on Figure 8 is due to the departure of
one of the H2O-ligand proton towards the solvent shell. From Figure 7, looking to the
Pt−N and unconstrained Pt−Cl mean bond lengths, it is interesting to outline that the
corresponding ligands are spectator of the reaction in agreement with the in-plane symmetry
of the transition state. This is well exemplified by the mean angle δ = (α+ β + γ)/3 which
remains fixed to 120◦ with standard deviation not exceeding 10◦ for both cases, showing
that there are only weak perturbations from outside the N−O−Cl plane.
By visualizing the constrained MD trajectories reported in the SI, it is rather clear that
the activated water molecule is embedded in a hydrogen-bond network throughout the whole
course of the aquation reaction. To quantify the number of first nearest neighbor solvent
molecules surrounding the H2O-reactant and Cl-product, the coordination numbers nOOw ,
(nOHw ,nHOw) and nClHw are plotted on Figure 8 as a function of ξ. They were evaluated
from the ensemble averages (cf. Sec. II B) by integrating the corresponding RDFs up to
standard radii51,80 of 3.2, 2.5 and 2.9 A˚, respectively. Even if at first sight the evolution
of n is somewhat erratic due to the short time sampling, we can extract some relevant
trends. At the beginning of the reaction, the inversely bonded water molecule integrates
around 3 solvent molecules respecting its H-bond donor[1]/acceptor[2] capacity. Around the
ion-dipole orientation region, as expected, H-bond acceptor (donor) capacity of the H2O-
reactant reduces (raises). At the transition state, around 2 and 1 solvent molecule(s) are
in close proximity of the activated H2O in cisplatin and pyriplatin, respectively. After this
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FIG. 8. Ensemble average of selected geometrical parameters describing the attack of inversely
bonded water molecule for cisplatin (left) and pyriplatin (right) aquation reaction. See also the
caption of Figure 7. Coordination numbers reported on the upper panel were evaluated from the
RDFs.
step, the average number acceptor-type H-bond continue to diminish whereas donor-type
stabilizes to 2. The evolution of the H2O-reactant H-bond network contrasts with the global
increase of the solvent shell size surrounding the Cl-product. Due the limited size of the
model nClHw never really stabilized to the reference value comprised between 5 and 6 as
obtained for free solvated chlorine anion.80
Finally, the BME aquation profiles and their analysis suggest that the aquation reaction
of cisplatin and its monofunctional derivatives presenting a Cl-leaving group is likely to be
independent of the charge state the type and number of N-donor ligands despite variations
in the mobility and microsolvation of the activated water molecule. Even if conditioned by
the choice of coordinate, the inverse hydration followed by the ion-dipole orientation seems
to be a prerequisite to reach the transition state.
IV. CONCLUSION AND OUTLOOK
In this work, reliable DFT-MD simulations of the aquation process of cisplatin and a set of
monofunctional platinum anticancer drugs have been performed using constrained dynamics
in conjuction with BME thermodynamic integration. Given the level of theory, accuracy
of about 1 kcal ·mol−1 has been reached on the activation barrier. For the set of square-
planar Pt(II) complexes, it is found that the kinetic of the reaction is independent of the
ligands and the charge state. It seems that the free enthalpies of reaction differ from a few
kcal ·mol−1 from one complex to another, and counterions can impact the thermodynamic
quantity with variations in the same range of magnitude. This result need to be confirmed
by performing larger scale DFT-MD simulations. We conclude that it is likely that the
mono and bifunctional platinum anticancer drugs behave the same way during the time
lapse between the cellular uptake and the DNA platination.
From a computational point of view, such kind of approach alleviates many intricacies
related to modelling chemical reactions in aqueous solvent which are commonly based on
isolated molecule approximation where thermodynamic quantities are computed from the
ideal gas approximation. Even if the protocol used here is computationally expensive,
we believe that it will become a routine task in near future along with the possibility of
increasing the system size and using more sophisticated exchange correlation functionals,
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especially with the Conquest code which have been developped to perform large scale
DFT simulations. This work opens the way for futur high level theoretical investigations of
the anticancer activity of monofuntional platinum complexes which are important steps for
approaching in silico design of new potent drugs.
1Wheate, N. J.; Walker, S.; Craig, G. E.; Oun, R. The status of platinum anticancer drugs in the clinic
and in clinical trials. Dalton Trans. 2010, 39, 8113–8127.
2Johnstone, T. C.; Park, G. Y.; Lippard, S. J. Understanding and Improving Platinum Anticancer Drugs
– Phenanthriplatin. Anticancer Res. 2014, 34, 471–476.
3Apps, M. G.; Choi, E. H. Y.; Wheate, N. J. The state-of-play and future of platinum drugs. Endocr.
Relat. Cancer 2015, 22, R219–R233.
4Johnstone, T. C.; Suntharalingam, K.; Lippard, S. J. The Next Generation of Platinum Drugs: Targeted
Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016, 116, 3436–3486.
5Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes. Drug Resistance Updates 2005,
8, 131–146.
6Chabner, B. A.; Roberts, T. G. Chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5, 65–72.
7Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7, 573–584.
8Hambley, T. W. The influence of structure on the activity and toxicity of Pt anti-cancer drugs. Coord.
Chem. Rev. 1997, 166, 181–223.
9Ziegler, C. J.; Silverman, A. P.; Lippard, S. J. High-throughput synthesis and screening of platinum drug
candidates. J. Biol. Inorg. Chem. 2000, 5, 774–783.
10Jamieson, E. R.; Lippard, S. J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem.
Rev. 1999, 99, 2467–2498.
11Dhar, S.; Lippard, S. J. In Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy;
Bonetti, A., Leone, R., Muggia, F. M., Howell, S. B., Eds.; Cancer Drug Discovery and Development;
Humana Press, 2009; pp 135–147.
12Vidossich, P.; Lledo´s, A.; Ujaque, G. First-Principles Molecular Dynamics Studies of Organometallic Com-
plexes and Homogeneous Catalytic Processes. Acc. Chem. Res. 2016, 49, 1271–1278; (a) Beret, E. C.;
Mart´ınez, J. M.; Pappalardo, R. R.; Sa´nchez Marcos, E.; Doltsinis, N. L.; Marx, D. Explaining Asymmetric
Solvation of Pt(II) versus Pd(II) in Aqueous Solution Revealed by Ab Initio Molecular Dynamics Simu-
lations. J. Chem. Theory Comput. 2008, 4, 2108–2121; (b) Beret, E. C.; Pappalardo, R. R.; Marx, D.;
Sa´nchez Marcos, E. Characterizing Pt-Derived Anticancer Drugs from First Principles: The Case of Ox-
aliplatin in Aqueous Solution. ChemPhysChem 2009, 10, 1044–1052; (c) Vidossich, P.; Ortun˜o, M. A´.;
Ujaque, G.; Lledo´s, A. Do Metal...Water Hydrogen Bonds Hold in Solution? Insight from Ab Initio
Molecular Dynamics Simulations. ChemPhysChem 2011, 12, 1666–1668.
13Truflandier, L. A.; Sutter, K.; Autschbach, J. Solvent Effects and Dynamic Averaging of 195Pt NMR
Shielding in Cisplatin Derivatives. Inorg. Chem. 2011, 50, 1723–1732.
14Sutter, K.; Truflandier, L. A.; Autschbach, J. NMR J-Coupling Constants in Cisplatin Derivatives Studied
by Molecular Dynamics and Relativistic DFT. ChemPhysChem 2011, 12, 1448–1455.
15Baidina, I. A.; Podberezskaya, N. V.; Krylova, L. F.; Borisov, S. V. Crystal structure of trans-
dichloroammineglycineplatinum (II) monohydrate trans-[PtNH3(H2NCH2COOH)Cl2]·H2O. J. Struct.
Chem. 1981, 22, 463–465.
16Rizzato, S.; Berge`s, J.; Mason, S. A.; Albinati, A.; Kozelka, J. Dispersion-Driven Hydrogen Bonding:
Predicted Hydrogen Bond between Water and Platinum(II) Identified by Neutron Diffraction. Angew.
Chem. Int. Ed. 2010, 49, 7440–7443.
17Kozelka, J.; Berge`s, J.; Attias, R.; Fraitag, J. Hydrogen Bond with a Strong Dispersion Component.
Angew. Chem. Int. Ed. 2000, 39, 198–201.
18Lopes, J. F.; Rocha, W. R.; Dos Santos, H. F.; De Almeida, W. B. Theoretical study of the potential
energy surface for the interaction of cisplatin and their aquated species with water. J. Chem. Phys. 2008,
128, 165103–14.
19Aono, S.; Mori, T.; Sakaki, S. 3D-RISM-MP2 Approach to Hydration Structure of Pt(II) and Pd(II)
Complexes: Unusual H-Ahead Mode vs Usual O-Ahead One. J. Chem. Theory Comput. 2016, 12, 1189–
1206.
20Berge`s, J.; Fourre´, I.; Pilme´, J.; Kozelka, J. Quantum Chemical Topology Study of the Water-Platinum(II)
Interaction. Inorg. Chem. 2013, 52, 1217–1227.
21Melchior, A.; Tolazzi, M.; Mart´ınez, J. M.; Pappalardo, R. R.; Sa´nchez Marcos, E. Hydration of Two
Cisplatin Aqua-Derivatives Studied by Quantum Mechanics and Molecular Dynamics Simulations. J.
Chem. Theory Comput. 2015, 11, 1735–1744.
22Kroutil, O.; Prˇedota, M.; Chval, Z. Pt···H Nonclassical Interaction in Water-Dissolved Pt(II) Complexes:
Coaction of Electronic Effects with Solvent-Assisted Stabilization. Inorg. Chem. 2016, 55, 3252–3264.
23Bancroft, D. P.; Lepre, C. A.; Lippard, S. J. Platinum-195 NMR kinetic and mechanistic studies of cis-
and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc. 1990, 112, 6860–6871.
24Knox, R. J.; Friedlos, F.; Lydall, D. A.; Roberts, J. J. Mechanism of Cytotoxicity of Anti-
cancer Platinum Drugs: Evidence That cis-Diamminedichloroplatinum(II) and cis-Diammine-(1,1-
cyclobutanedicarboxylato)platinum(II) Differ Only in the Kinetics of Their Interaction with DNA. Cancer
Res. 1986, 46, 1972–1979.
15
25Alberts, D. S.; Dorr, R. T. New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment
of Solid Tumors. The Oncologist 1998, 3, 15–34.
26Johnstone, T. C.; Alexander, S. M.; Wilson, J. J.; Lippard, S. J. Oxidative halogenation of cisplatin and
carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs. Dalton
Trans. 2014, 44, 119–129.
27Blommaert, F. A.; van Dijk-Knijnenburg, H. C. M.; Dijt, F. J.; den Engelse, L.; Baan, R. A.; Berends, F.;
Fichtinger-Schepman, A. M. J. Formation of DNA Adducts by the Anticancer Drug Carboplatin: Different
Nucleotide Sequence Preferences in Vitro and in Cells. Biochemistry 1995, 34, 8474–8480.
28Zhang, Y.; Guo, Z.; You, X. Hydrolysis Theory for Cisplatin and Its Analogues Based on Density Func-
tional Studies. J. Am. Chem. Soc. 2001, 123, 9378–9387; (a) Robertazzi, A.; Platts, J. A. Hydrogen bond-
ing, solvation, and hydrolysis of cisplatin: A theoretical study. J. Comput. Chem. 2004, 25, 1060–1067;
(b) Lau, J. K.; Deubel, D. V. Hydrolysis of the Anticancer Drug Cisplatin: Pitfalls in the Interpretation
of Quantum Chemical Calculations. J. Chem. Theory Comput. 2006, 2, 103–106; (c) Alberto, M. E.;
Lucas, M. F. A.; Pavelka, M.; Russo, N. The Second-Generation Anticancer Drug Nedaplatin: A The-
oretical Investigation on the Hydrolysis Mechanism. J. Phys. Chem. B 2009, 113, 14473–14479; (d)
Lucas, M. F. A.; Pavelka, M.; Alberto, M. E.; Russo, N. Neutral and Acidic Hydrolysis Reactions of the
Third Generation Anticancer Drug Oxaliplatin. J. Phys. Chem. B 2009, 113, 831–838; (e) Banerjee, S.;
Sengupta, P. S.; Mukherjee, A. K. Trans Platinum Anticancer Drug AMD443: A Detailed Theoretical
Study by DFT-TST Method on the Hydrolysis Mechanism. Chem. Phys. Lett. 2010, 487, 108–115; (f)
Melchior, A.; Marcos, E. S.; Pappalardo, R. R.; Mart´ınez, J. M. Comparative study of the hydrolysis of
a third- and a first-generation platinum anticancer complexes. Theor. Chem. Acc. 2010, 128, 627–638.
29Carloni, P.; Sprik, M.; Andreoni, W. Key Steps of the cis-Platin-DNA Interaction: Density Functional
Theory-Based Molecular Dynamics Simulations. J. Phys. Chem. B 2000, 104, 823–835.
30Lau, J. K.-C.; Ensing, B. Hydrolysis of cisplatin—a first-principles metadynamics study. Phys. Chem.
Chem. Phys. 2010, 12, 10348–10355.
31Yokogawa, D.; Sato, H.; Sakaki, S. New generation of the reference interaction site model self-consistent
field method: Introduction of spatial electron density distribution to the solvation theory. J. Chem. Phys.
2007, 126, 244504.
32Yokogawa, D.; Sato, H.; Sakaki, S. Analytical energy gradient for reference interaction site model self-
consistent field explicitly including spatial electron density distribution. J. Chem. Phys. 2009, 131,
214504.
33Yokogawa, D.; Ono, K.; Sato, H.; Sakaki, S. Theoretical study on aquation reaction of cis-platin complex:
RISM–SCF–SEDD, a hybrid approach of accurate quantum chemical method and statistical mechanics.
Dalton Trans. 2011, 40, 11125–11130.
34Hollis, L. S.; Amundsen, A. R.; Stern, E. W. Chemical and biological properties of a new series of cis-
diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor) Cl]+.
J. Med. Chem. 1989, 32, 128–136.
35Brabec, V. DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and
repair. Prog. Nucleic Acid Res. Mol. Biol. 2002, 71, 1–68.
36Bursova, V.; Kasparkova, J.; Hofr, C.; Brabec, V. Effects of Monofunctional Adducts of Platinum(II)
Complexes on Thermodynamic Stability and Energetics of DNA Duplexes. Biophys. J. 2005, 88, 1207–
1214.
37Lovejoy, K. S.; Todd, R. C.; Zhang, S.; McCormick, M. S.; D’Aquino, J. A.; Reardon, J. T.; Sancar, A.; Gi-
acomini, K. M.; Lippard, S. J. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II)
antitumor agent: Uptake, structure, function, and prospects. PNAS 2008, 105, 8902–8907.
38Wang, D.; Zhu, G.; Huang, X.; Lippard, S. J. X-ray structure and mechanism of RNA polymerase II
stalled at an antineoplastic monofunctional platinum-DNA adduct. PNAS 2010, 107, 9584–9589.
39Zhu, G.; Myint, M.; Ang, W. H.; Song, L.; Lippard, S. J. Monofunctional Platinum–DNA Adducts Are
Strong Inhibitors of Transcription and Substrates for Nucleotide Excision Repair in Live Mammalian
Cells. Cancer Res. 2012, 72, 790–800.
40Park, G. Y.; Wilson, J. J.; Song, Y.; Lippard, S. J. Phenanthriplatin, a monofunctional DNA-binding
platinum anticancer drug candidate with unusual potency and cellular activity profile. PNAS 2012, 109,
11987–11992.
41Johnstone, T. C.; Alexander, S. M.; Lin, W.; Lippard, S. J. Effects of Monofunctional Platinum Agents
on Bacterial Growth: A Retrospective Study. J. Am. Chem. Soc. 2014, 136, 116–118.
42Bowler, D. R.; Choudhury, R.; Gillan, M. J.; Miyazaki, T. Recent progress with large-scale ab initio
calculations: the CONQUEST code. phys. stat. sol. (b) 2006, 243, 989–1000.
43Bowler, D. R.; Miyazaki, T. Calculations for millions of atoms with density functional theory: linear
scaling shows its potential. J. Phys.: Condens. Matter 2010, 22, 074207.
44Herna´ndez, E.; Gillan, M. J.; Goringe, C. M. Linear-scaling density-functional-theory technique: The
density-matrix approach. Phys. Rev. B 1996, 53, 7147.
45Sankey, O. F.; Niklewski, D. J. Ab initio multicenter tight-binding model for molecular-dynamics simu-
lations and other applications in covalent systems. Phys. Rev. B 1989, 40, 3979–3995.
46Junquera, J.; Paz, O´.; Sa´nchez-Portal, D.; Artacho, E. Numerical atomic orbitals for linear-scaling calcu-
lations. Phys. Rev. B 2001, 64, 235111.
47Torralba, A. S.; Todorovic´, M.; Bra´zdova´, V.; Choudhury, R.; Miyazaki, T.; Gillan, M. J.; Bowler, D. R.
Pseudo-atomic orbitals as basis sets for the O(N) DFT code CONQUEST. J. Phys.: Condens. Matter
16
2008, 20, 294206.
48Troullier, N.; Martins, J. L. Efficient pseudopotentials for plane-wave calculations. Phys. Rev. B 1991,
43, 1993–2006.
49Perdew, J. P.; Burke, K.; Ernzerhof, M. Generalized Gradient Approximation Made Simple. Phys. Rev.
Lett. 1996, 77, 3865–3868.
50Lin, I.-C.; Seitsonen, A. P.; Tavernelli, I.; Rothlisberger, U. Structure and Dynamics of Liquid Water
from ab Initio Molecular Dynamics—Comparison of BLYP, PBE, and revPBE Density Functionals with
and without van der Waals Corrections. J. Chem. Theory Comput. 2012, 8, 3902–3910.
51DiStasio, R. A.; Santra, B.; Li, Z.; Wu, X.; Car, R. The individual and collective effects of exact exchange
and dispersion interactions on the ab initio structure of liquid water. J. Chem. Phys. 2014, 141, 084502.
52Truflandier, L. A.; Autschbach, J. Probing the Solvent Shell with 195Pt Chemical Shifts: Density Func-
tional Theory Molecular Dynamics Study of Pt(II) and Pt(IV) Anionic Complexes in Aqueous Solution.
J. Am. Chem. Soc. 2010, 132, 3472–3483.
53Verlet, L. Computer ”Experiments” on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones
Molecules. Phys. Rev. 1967, 159, 98–103.
54Martyna, G. J.; Klein, M. L.; Tuckerman, M. Nose´–Hoover chains: The canonical ensemble via continuous
dynamics. J. Chem. Phys. 1992, 97, 2635–2643.
55Hirakawa, T.; Suzuki, T.; Bowler, D. R.; Miyazaki, T. Canonical-ensemble extended Lagrangian
Born–Oppenheimer molecular dynamics for the linear scaling density functional theory. J. Phys.: Con-
dens. Matter 2017, 29, 405901.
56Carter, E.; Ciccotti, G.; Hynes, J. T.; Kapral, R. Constrained reaction coordinate dynamics for the
simulation of rare events. Chem. Phys. Lett. 1989, 156, 472–477.
57Sprik, M.; Ciccotti, G. Free energy from constrained molecular dynamics. J. Chem. Phys. 1998, 109,
7737–7744.
58Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. Numerical integration of the cartesian equations of motion
of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327–341.
59Andersen, H. C. Rattle: A “velocity” version of the shake algorithm for molecular dynamics calculations.
J. Comput. Phys. 1983, 52, 24–34.
60Ciccotti, G.; Ryckaert, J.-P. Molecular dynamics simulation of rigid molecules. Comp. Phys. Rep. 1986,
4, 346–392.
61Jacucci, G.; Rahman, A. Comparing the efficiency of Metropolis Monte Carlo and molecular-dynamics
methods for configuration space sampling. Il Nuovo Cimento D 1984, 4, 341–356.
62Giannozzi, P.; et al., J. Phys.: Condens. Matter 2009, 21, 395502.
63Frisch, M. J.; et al., Gaussian09. Gaussian 09, Revision A.02; Gaussian, Inc., Wallingford, CT, 2009
64Press, W. H.; Flannery, B. P.; Teukolsky, S. A.; Vetterling, W. T. Numerical Recipes in Fortran 77: The
Art of Scientific Computing, 2nd ed.; Cambridge University Press: Cambridge England ; New York, NY,
USA, 1992.
65Lau, J. K.; Ensing, B. Hydrolysis of cisplatina first-principles metadynamics study. Phys. Chem. Chem.
Phys. 2010,
66Nakamoto, K.; McCarthy, P. J.; Fujita, J.; Condrate, R. A.; Behnke, G. T. Infrared Studies of Ligand-
Ligand Interaction in Dihalogenodiammineplatinum(II) Complexes. Inorg. Chem. 1965, 4, 36–43.
67Wysokin´ski, R.; Michalska, D. The performance of different density functional methods in the calculation
of molecular structures and vibrational spectra of platinum(II) antitumor drugs: cisplatin and carboplatin.
J. Comput. Chem. 2001, 22, 901–912.
68Raugei, S.; Cardini, G.; Schettino, V. An ab initio molecular dynamics study of the SN2 reaction
Cl−+CH3Br→CH3Cl+Br−. The Journal of Chemical Physics 1999, 111, 10887–10894.
69Yang, S.-Y.; Fleurat-Lessard, P.; Hristov, I.; Ziegler, T. Free Energy Profiles for the Identity SN2 Reactions
Cl− + CH3Cl and NH3 + H3BNH3: A Constraint Ab Initio Molecular Dynamics Study. J. Phys. Chem.
A 2004, 108, 9461–9468.
70Bu¨hl, M.; Kabrede, H. Mechanism of Water Exchange in Aqueous Uranyl(VI) Ion. A Density Functional
Molecular Dynamics Study. Inorg. Chem. 2006, 45, 3834–3836.
71Komeiji, Y.; Ishikawa, T.; Mochizuki, Y.; Yamataka, H.; Nakano, T. Fragment Molecular Orbital method-
based Molecular Dynamics (FMO-MD) as a simulator for chemical reactions in explicit solvation. J.
Comput. Chem. 2009, 30, 40–50.
72Miller, S. E.; House, D. A. The hydrolysis products of cis-diamminedichloroplatinum(II). 1. The kinetics
of formation and anation of the cis-diammine(aqua)chloroplatinum(II) cation in acidic aqueous solution.
Inorg. Chim. Acta 1989, 161, 131–137.
73Miller, S. E.; House, D. A. The hydrolysis products of cis-dichlorodiammineplatinum(II) 2. The kinetics
of formation and anation of the cis-diamminedi(aqua)platinum(II) cation. Inorg. Chim. Acta 1989, 166,
189–197.
74Miller, S. E.; House, D. A. The hydrolysis products of cis-dichlorodiammineplatinum(II) 3. Hydrolysis
kinetics at physiological pH. Inorg. Chim. Acta 1990, 173, 53–60.
75Reishus, J. W.; Martin, D. S. cis-Dichlorodiammineplatinum(II). Acid Hydrolysis and Isotopic Exchange
of the Chloride Ligands. J. Am. Chem. Soc. 1961, 83, 2457–2462.
76Marti, N.; Bon Hoa, G. H.; Kozelka, J. Reversible hydrolysis of [PtCl(dien)]+ and [PtCl(NH3)3]+. De-
termination of the rate constants using UV spectrophotometry. Inorg. Chem. Comm. 1998, 1, 439–442.
77Davies, M. S.; Berners-Price, S. J.; Hambley, T. W. Slowing of Cisplatin Aquation in the Presence of
17
DNA but Not in the Presence of Phosphate: Improved Understanding of Sequence Selectivity and the
Roles of Monoaquated and Diaquated Species in the Binding of Cisplatin to DNA. Inorg. Chem. 2000,
39, 5603–5613.
78Lee, K. W.; Martin, D. S. Cis-dichlorodiammineplatinum(II). Aquation equilibria and isotopic exchange
of chloride ligands with free chloride and tetrachloroplatinate(II). Inorg. Chim. Acta 1976, 17, 105–110.
79Vinje, J.; Sletten, E.; Kozelka, J. Influence of dT20 and [d(AT)10]2 on Cisplatin Hydrolysis Studied by
Two-Dimensional [1H,15N] HMQC NMR Spectroscopy. Chem. Eur. J. 2005, 11, 3863–3871.
80Zhang, C.; Pham, T. A.; Gygi, F.; Galli, G. Communication: Electronic structure of the solvated chloride
anion from first principles molecular dynamics. J. Chem. Phys. 2013, 138, 181102.
